Published in Mental Health Business Week, January 2nd, 2010
"To characterise the use of LAIs in people with schizophrenia in three clinical settings in the UK. The study used audit data from quality improvement programmes conducted by the Prescribing observatory for Mental Health. Long-acting injections were found to be prescribed for between a quarter and a third of patients, depending on the clinical setting. Flupentixol,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Business Week